Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela M Minassian

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 9, 2022
Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled TrialPaul T Heath, Eva P Galiza, David Neil Baxter, et al.
Nature Communications|September 25, 2025
Development of clinical immunity to Plasmodium vivax following repeat controlled human malaria infectionMimi M Hou, Adam C Harding, Natalie M Barber, et al.
The Lancet. Infectious Diseases|June 16, 2024
Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trialSarah E Silk, Wilmina F Kalinga, Jo Salkeld, et al.
Cell|July 26, 2024
Analysis of the diverse antigenic landscape of the malaria protein RH5 identifies a potent vaccine-induced human public antibody clonotypeJordan R Barrett, Dimitra Pipini, Nathan D Wright, et al.
JCI Insight|October 5, 2021
Controlled human malaria infection with a clone of Plasmodium vivax with high-quality genome assemblyAngela M Minassian, Yrene Themistocleous, Sarah E Silk, et al.
JCI Insight|November 3, 2017
Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactionsRuth O Payne, Sarah E Silk, Sean C Elias, et al.
The Journal of Infection|August 9, 2025
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trialLeila Janani, Alasdair P S Munro, Annie Wright, et al.
The Lancet. Infectious Diseases|May 13, 2022
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trialAlasdair P S Munro, Shuo Feng, Leila Janani, et al.
Med (New York, N.Y.)|July 5, 2021
Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccinationAngela M Minassian, Sarah E Silk, Jordan R Barrett, et al.
Lancet (London, England)|December 5, 2021
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trialAlasdair P S Munro, Leila Janani, Victoria Cornelius, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 9, 2022
Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled TrialPaul T Heath, Eva P Galiza, David Neil Baxter, et al.
Nature Communications|September 25, 2025
Development of clinical immunity to Plasmodium vivax following repeat controlled human malaria infectionMimi M Hou, Adam C Harding, Natalie M Barber, et al.
The Lancet. Infectious Diseases|June 16, 2024
Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trialSarah E Silk, Wilmina F Kalinga, Jo Salkeld, et al.
Cell|July 26, 2024
Analysis of the diverse antigenic landscape of the malaria protein RH5 identifies a potent vaccine-induced human public antibody clonotypeJordan R Barrett, Dimitra Pipini, Nathan D Wright, et al.
JCI Insight|October 5, 2021
Controlled human malaria infection with a clone of Plasmodium vivax with high-quality genome assemblyAngela M Minassian, Yrene Themistocleous, Sarah E Silk, et al.
JCI Insight|November 3, 2017
Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactionsRuth O Payne, Sarah E Silk, Sean C Elias, et al.
The Journal of Infection|August 9, 2025
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trialLeila Janani, Alasdair P S Munro, Annie Wright, et al.
The Lancet. Infectious Diseases|May 13, 2022
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trialAlasdair P S Munro, Shuo Feng, Leila Janani, et al.
Med (New York, N.Y.)|July 5, 2021
Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccinationAngela M Minassian, Sarah E Silk, Jordan R Barrett, et al.
Lancet (London, England)|December 5, 2021
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trialAlasdair P S Munro, Leila Janani, Victoria Cornelius, et al.
Pageof 7